Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine What is the pipeline for future medications for obesity? International Journal of Obesity Three new #obesity drugshigh dose semaglutide, semaglutide plus cagrilintide, and oral orforglipronmay soon be approved in the US. JAMA Medical News Director Jennifer Abbasi and Lead Senior Staff Writer Rita Rubin examine how Recent advances in peptide based therapies for obesity and type 2 diabetes ScienceDirect Targeting the weight within: obesity pharmacotherapy in cardiovascular disease Medicine Today